risperidone has been researched along with Duncan Disease in 1 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velnati, S | 1 |
| Ruffo, E | 1 |
| Massarotti, A | 1 |
| Talmon, M | 1 |
| Varma, KSS | 1 |
| Gesu, A | 1 |
| Fresu, LG | 1 |
| Snow, AL | 1 |
| Bertoni, A | 1 |
| Capello, D | 1 |
| Tron, GC | 1 |
| Graziani, A | 1 |
| Baldanzi, G | 1 |
1 other study available for risperidone and Duncan Disease
| Article | Year |
|---|---|
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lympho | 2019 |